-
Part 3 | Session 4 ESC 25 Guidelines Discussion: Management of Dyslipidaemias
-
Part 3 | Session 5 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
-
Part 4 | Session 1 TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
-
Part 4 | Session 2 The VICTOR & VICTORIA Pooled Analysis
-
Part 4 | Session 4 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism
-
Part 4 | Session 6 STEEER-AF Cluster Randomised Trial by the ESC and EHRA
-
Part 4 | Session 7 NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency
-
Part 4 | Session 9 SWEDEPAD 1 and 2: Drug-Coated Devices in Peripheral Arterial Disease
-
Part 4 | Session 10 Lifetime Benefits of Combination Therapy in HFpEF
-
Part 4 | Session 11 REBOOT-CNIC: Beta-blockers After Infarction with LVEF Greater Than 40%
-
Part 4 | Session 12 ODYSSEY-HCM: Mavacamten in Non-obstructive Hypertrophic Cardiomyopathy
-
Part 4 | Session 13 Pooled MACE Data for Obicetrapib
-
Part 4 | Session 14 STRIDE: Outcomes by Sex
-
Part 4 | Session 15 The SEMA-VR CardioLink-15 Trial
-
Part 4 | Session 16 The CARUSO Trial: Carotid Plaques Stabilisation and Regression with Evolocumab
-
Part 4 | Session 17 EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
-
Part 1 | Session 1 View from the Thoraxcenter: ESC 25 Late-breaking Science Wrap-Up
-
Part 1 | Session 2 View from the Thoraxcenter: What's Hot at ESC 25?
-
Part 2 | Session 1 Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
Part 2 | Session 2 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
Part 2 | Session 3 Day 2 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
Part 2 | Session 4 Day 1 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
Part 3 | Session 1 VICTOR: Vericiguat in Heart Failure
-
Part 3 | Session 2 DIGIT-HF: Cardiac Glycosides in HFrEF
ESC Congress 2025 - Long-term beta-blocker therapy after myocardial infarction reduced the primary endpoint of death from any cause or major adverse cardiovascular events.
Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Dan Atar (Oslo University Hospital Ulleval, NO) and Dr Anna Meta Dyrvig Kristensen (Bispebjerg and Frederiksberg Hospital, DK) to discuss the latest findings from the combined BETAMI-DANBLOCK trial evaluating beta-blocker therapy after myocardial infarction.
This landmark event-driven trial represents the largest modern evaluation of beta-blocker efficacy in post-MI patients, combining the Danish DANBLOCK and Norwegian BETAMI studies to randomise approximately 5,700 patients with normal or mildly reduced left ventricular ejection fraction (LVEF ≥ 40%) to open-label beta-blocker therapy or no such treatment.
Findings presented first at ESC.25 showed that when administered within 14 days of MI, long-term beta-blocker therapy was found to reduce death from any cause or major adverse cardiovascular events.
Recorded onsite at ESC Congress 2025 in Madrid.
Editors: Jordan Rance and Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Dive into our coverage of ESC Congress 2025 for groundbreaking trial results and discussions with expert faculty.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- Watch our Wrap-Up series led by Dr Mirvat Alasnag summarising the key take-aways from each day of the congress.
- For clinical trial data from principal investigators, keep up with Dr Harriette Van Spall's Late-Breaker Discussion series.
- Our concise, accessible Expert Interviews will focus on the current data and it's impact on clinical practice.
- Don't miss the Highlights series to stay ahead of the curve in each field.
- In the Journal Discussions series, authors of ECR Journal explore their special focuses in depth.
More from this programme
Part 1
View from the Thoraxcenter: What's Hot at ESC 25?
Part 2
Daily Wrap Ups with Dr Mirvat Alasnag
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Dan Atar
Professor of Cardiology
Prof Dan Atar is Head of Research and Professor of Cardiology at the University of Oslo, Oslo, NO. He studied medicine in Basel and was then trained in internal medicine and cardiology.
Prof Atar joined John Hopkins University in Baltimore (1991–1994) and the University of Copenhagen, where he worked as a senior cardiologist. From 1997 to 1998 Dan Atar served as senior physician, supported by the Cloëtta Foundation of Cardiology at the University Hospital of Zurich.
Prof Atar has written over 480 articles and book chapters (H-index 78) and holds the fellowship-titles FESC, FACC, FEHRA and inaugural FAHA. He served as Chairman of the ESC Working Group on Cardiovascular Pharmacotherapy. He was on several ESC guideline writing committees, amongst others the 2010, 2012 and 2016 ESC Guidelines on Atrial Fibrillation, the 2012 STEMI-Guidelines and the 2018 Universal Definition of AMI. In 2012 Professor Atar was elected as Councilor and Board member, in 2014 as Vice…
Comments